Eli Lilly and Company $LLY Stock Holdings Lifted by NTV Asset Management LLC

NTV Asset Management LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 31,222 shares of the company’s stock after acquiring an additional 611 shares during the quarter. Eli Lilly and Company makes up 3.3% of NTV Asset Management LLC’s investment portfolio, making the stock its 4th biggest position. NTV Asset Management LLC’s holdings in Eli Lilly and Company were worth $36,126,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Sowell Financial Services LLC lifted its holdings in shares of Eli Lilly and Company by 8.0% in the 3rd quarter. Sowell Financial Services LLC now owns 8,229 shares of the company’s stock worth $9,522,000 after acquiring an additional 608 shares during the last quarter. One Wealth Capital Management LLC boosted its stake in shares of Eli Lilly and Company by 60.7% in the 3rd quarter. One Wealth Capital Management LLC now owns 1,218 shares of the company’s stock valued at $1,409,000 after purchasing an additional 460 shares in the last quarter. Ascent Wealth Partners LLC purchased a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $10,570,000. Blodgett Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Blodgett Wealth Advisors LLC now owns 3,806 shares of the company’s stock valued at $4,404,000 after purchasing an additional 27 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc grew its holdings in shares of Eli Lilly and Company by 3.1% during the 3rd quarter. Nabity Jensen Investment Management Inc now owns 1,711 shares of the company’s stock valued at $1,980,000 after purchasing an additional 51 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A U.S. judge declined to block Eli Lilly’s advertising for its weight-loss drugs in a case brought by Novo Nordisk. The ruling supports Lilly’s ability to market its obesity treatments and represents a favorable development in the competitive GLP-1 market. US judge won’t block Eli Lilly ads for weight-loss drugs
• Positive Sentiment: New clinical data for investigational lung-cancer drug olomorasib showed durable first-line activity in KRAS G12C-mutated non-small-cell lung cancer, strengthening Lilly’s pipeline beyond its obesity and diabetes franchises. New data on Lilly’s investigational treatment olomorasib
• Positive Sentiment: Early Phase 1 results for Lilly’s investigational sofe-m plus bevacizumab regimen in ovarian cancer showed high response and disease-control rates without major new safety signals. Although preliminary, the data add potential long-term value to the oncology pipeline. Lilly reports strong Phase 1 ovarian cancer data
• Positive Sentiment: The board declared a quarterly dividend of $1.73 per share, payable December 10 to shareholders of record November 13. The announcement provides a modest signal of financial confidence, though the dividend is not likely to be the primary stock catalyst. Lilly declares fourth-quarter 2026 dividend
• Neutral Sentiment: Analysts have high expectations for the October 29 earnings report, with investors focused on demand for weight-loss drugs, prescription trends, manufacturing capacity and updated full-year guidance. A strong report could extend the rally, while any miss could prompt volatility. Wall Street has high expectations for Eli Lilly
• Negative Sentiment: Competition from Novo Nordisk and broader pricing, patent and market-access pressures remain risks. Analysts also caution that revenue could temporarily soften even as patient numbers grow, while Lilly’s elevated valuation leaves the stock sensitive to weaker-than-expected guidance. Why revenue could dip even as patients grow

Analyst Ratings Changes

A number of brokerages recently commented on LLY. Sanford C. Bernstein reiterated an “outperform” rating and issued a $1,450.00 target price on shares of Eli Lilly and Company in a research report on Monday. Morgan Stanley boosted their price target on shares of Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. The Goldman Sachs Group restated a “buy” rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. Leerink Partners raised their price objective on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a research note on Wednesday, October 21st. Finally, Wells Fargo & Company raised their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,320.25.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,279.29 on Tuesday. The firm has a market cap of $1.20 trillion, a PE ratio of 42.93, a price-to-earnings-growth ratio of 1.71 and a beta of 0.46. Eli Lilly and Company has a fifty-two week low of $809.63 and a fifty-two week high of $1,321.21. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The business has a 50 day moving average price of $1,187.35 and a 200-day moving average price of $1,086.38.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter last year, the business earned $6.31 earnings per share. The business’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts predict that Eli Lilly and Company will post 33.22 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is currently 23.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $15,958,170 in the last quarter. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.